Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blueprint Medicines Corp.

www.blueprintmedicines.com

Latest From Blueprint Medicines Corp.

Ipsen Doubles Down On FOP With Blueprint Pact

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

Companies Rare Diseases

Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.

Business Strategies Clinical Trials

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Clinical Trials Cancer

Blueprint Medicines Aims For Genomically Defined GIST Indication With Avapritinib NDA

Kinome-focused Blueprint Medicines plans to follow up its first NDA, for all lines of therapy in patients with exon 18 mutant GIST or fourth-line use in non-genomically selected patients, with submissions for third-line GIST and advanced systemic mastocytosis in 2020.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Blueprint Medicines Corp.
  • Senior Management
  • Jeffrey Albers, Pres. & CEO
    Mike Landsittel, CFO
    Marion Dorsch, PhD, CSO
    Anthony Boral, MD, PhD, CMO
    Kathryn Haviland, COO
  • Contact Info
  • Blueprint Medicines Corp.
    Phone: (617) 374-7580
    45 Sydney St.
    Ste. 200
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register